Neopharmed Gentili Madirel

Madirel is a pharmaceutical product used for hypertension, produced by Neopharmed Gentili. This brand has deep roots in Italian pharmacology, originating from the merger of two historic entities: Neopharmed and Gentili. For many years, the brand was part of international groups, but it returned to significant Italian private equity control in recent years. Specifically, since 2022, the majority stake is held by the global investment firm Ardian, in partnership with the Mediolanum Farmaceutici group, ensuring the company remains headquartered in Milan while benefiting from international capital for growth and development. Manufacturing is primarily concentrated in Italy to maintain high quality standards for the European market.